Your browser doesn't support javascript.
loading
Risk factors for incident venous thromboembolism in active cancer patients: A population based case-control study.
Ashrani, Aneel A; Gullerud, Rachel E; Petterson, Tanya M; Marks, Randolph S; Bailey, Kent R; Heit, John A.
Affiliation
  • Ashrani AA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States. Electronic address: ashrani.aneel@mayo.edu.
  • Gullerud RE; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Petterson TM; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Marks RS; Division of Medical Oncology, Department of Oncology, Mayo Clinic, Rochester, MN, United States.
  • Bailey KR; Division of Biomedical Statistics and Informatics, Department of Health Sciences Research, Mayo Clinic, Rochester, MN, United States.
  • Heit JA; Division of Hematology, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States; Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, Rochester, MN, United States; Division of Epidemiology, Department of Health Sciences Research, Mayo Clinic, Rocheste
Thromb Res ; 139: 29-37, 2016 Mar.
Article de En | MEDLINE | ID: mdl-26916293
ABSTRACT

BACKGROUND:

Independent risk factors for cancer-associated incident venous thromboembolism (VTE) and their magnitude of risk are not fully characterized.

AIM:

To identify non-cancer and cancer-specific risk factors for cancer-associated incident VTE.

METHODS:

In a population-based retrospective case-control study, we used Rochester Epidemiology Project and Mayo Clinic Cancer Registry resources to identify all Olmsted County, MN residents with active cancer-associated incident VTE, 1973-2000 (cases; n=570) and 1-3 residents with active cancer matched to each case on age, sex, date and duration of active cancer (controls; n=604). Using conditional logistic regression, we tested cancer and non-cancer characteristics for an association with VTE, including a cancer site VTE risk score.

RESULTS:

In the multivariable model, higher cancer site VTE risk score (OR=1.4 per 2-fold increase), cancer stage≥2 (OR=2.2), liver metastasis (OR=2.7), chemotherapy (OR=1.8) and progesterone use (OR=2.1) were independently associated with VTE, as were BMI<18.5kg/m(2) (OR=1.9) or ≥35kg/m(2) (OR=4.0), hospitalization (OR=7.9), nursing home confinement (OR=4.7), central venous (CV) catheter (OR=8.5) and any recent infection (OR=1.7). In a subgroup analysis, platelet count≥350×10(9)/L at time of cancer diagnosis was marginally associated with VTE (OR=2.3, p=0.07).

CONCLUSION:

Cancer site, cancer stage≥2, liver metastasis, chemotherapy, progesterone, being underweight or obese, hospitalization/nursing home confinement, CV catheter, and infection are independent risk factors for incident VTE in active cancer patients.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thromboembolisme veineux / Tumeurs Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Thromb Res Année: 2016 Type de document: Article

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Thromboembolisme veineux / Tumeurs Type d'étude: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limites: Aged / Aged80 / Female / Humans / Male / Middle aged Langue: En Journal: Thromb Res Année: 2016 Type de document: Article